ライフサイエンスコーパス: major bleeding

1 omposite of major or clinically relevant non-major bleeding).

2 TIMI (Thrombolysis In Myocardial Infarction) major bleeding.

3 iated with low risk of recurrent spontaneous major bleeding.

4 The principal safety endpoint was major bleeding.

5 eduction in ischaemic stroke and increase in major bleeding.

6 obability of HIT-related thromboembolism and major bleeding.

7 ant reduction in the incidence of stroke and major bleeding.

8 The principal safety outcome was major bleeding.

9 S led to improved predictive performance for major bleeding.

10 before angiography, including 52 (0.4%) with major bleeding.

11 ould be superior to bridging with respect to major bleeding.

12 , 1.15-1.31) and a borderline higher risk of major bleeding.

13 ality, myocardial infarction, or stroke) and major bleeding.

14 nts and having a reduced propensity to cause major bleeding.

15 The primary safety end point was major bleeding.

16 al thromboembolism and decreased the risk of major bleeding.

17 embolism, or transient ischemic attack) and major bleeding.

18 e thrombosis or thrombosis-related death and major bleeding.

19 ith TTR and log INR variability, but not for major bleeding.

20 death, reinfarction, recurrent ischemia, and major bleeding.

21 years old but does not increase the risk of major bleeding.

22 stroke, or non-coronary artery bypass graft major bleeding.

23 ion of LMWH, and the secondary end point was major bleeding.

24 bolism, and the principal safety outcome was major bleeding.

25 uced major adverse limb events and increased major bleeding.

26 recurrent VTE and primary safety outcome was major bleeding.

27 e aspirin alone, but at an increased risk of major bleeding.

28 The main safety outcome was major bleeding.

29 mortality, and was not associated with more major bleeding.

30 alone, was associated with increased risk of major bleeding.

31 syndrome but did result in a higher risk of major bleeding.

32 lowered major vascular events, but increased major bleeding.

33 , but did significantly increase the risk of major bleeding.

34 0-35 days and the primary safety outcome was major bleeding.

35 were in-hospital stroke, renal failure, and major bleeding.

36 tcome of recurrent venous thromboembolism or major bleeding.

37 2.5%; HR 1.03, 95% CI 0.78-1.36; P=0.84), or major bleeding (1.9% vs 1.8%; HR 1.15, 95% CI 0.83-1.59;

38 3 to 9.95 percentage points]; P < 0.001) and major bleeding (10.5% vs. 7.7%; difference, 2.8 percenta

39 There were no differences in major bleeding (12 patients for tinzaparin vs 11 patient

40 Major bleeding (13.8% versus 5.4%; hazard ratio, 2.64; 9

41 dial infarction (2.9% versus 0.2%; P<0.001), major bleeding (14.0% versus 0.9%; P<0.001), blood trans

42 with CABG was associated with lower rates of major bleeding (15.3% versus 55.6%; P<0.0001), blood tra

43 ) or the secondary bleeding endpoint of TIMI major bleeding (16 [5.3%] vs. 12 [4.0%]; HR: 1.35; 95% C

44 arization (22.8% versus 13.0%; P=0.006), and major bleeding (23.5% versus 8.4%; P<0.0001).

45 +/- GPI resulted in reduced 30-day rates of major bleeding (4.2% vs. 7.8%; relative risk [RR]: 0.53;

46 there was 1 death (in the heparin group), no major bleeding, 4 minor bleeding episodes (3 in the USAT

47 No treatment-related differences in major bleeding (5.6% vs. 5.7%; HR: 1.00; 95% CI: 0.50 to

48 For major bleeding, a tenecteplase-based regimen tended to b

49 nce of periprocedural myocardial infarction, major bleeding, acute kidney injury, and new-onset atria

50 dney disease, anemia, coagulopathy, obesity, major bleeding, acute myocardial infarction, vascular co

51 tes of stroke/systemic embolic event (SSEE), major bleeding, additional efficacy and safety outcomes,

52 18-1.68) and nonmajor clinically relevant or major bleeding (adjusted hazard ratio, 1.47 for >/= 10 v

53 ed EHR use was associated with lower risk of major bleeding (adjusted odds ratio, 0.78 [confidence in

54 Safety was inversely related to major bleeding (adjusted odds ratio-10% increment, 0.93;

55 Ds are associated with a modest reduction in major bleeding after PCI.

56 dysfunction were independent risk factors of major bleeding (all p < 0.05).

57 ortality and procedural success, but reduced major bleeding and access site complications, compared w

58 erse clinical events, through a reduction in major bleeding and all-cause mortality.

59 Annual rates of any major bleeding and any thromboembolism in iTTR less than

60 Rates of major bleeding and coronary thrombotic events were no di

61 fit to bring greater clarity to NOAC-related major bleeding and efficacy at preventing stroke specifi

62 ent rates of stroke or systemic embolism and major bleeding and hazard ratios (HRs) and 95% CIs were

63 st predictive and discriminatory ability for major bleeding and ICH in an Asian/Chinese AF population

64 The risks of major bleeding and intracranial hemorrhage (ICH) are hig

65 d rates of thrombotic/cardiovascular events, major bleeding and mortality were recorded.

66 levation MI, slightly lower adjusted risk of major bleeding and mortality were seen in hospitals impl

67 cy (stroke or systemic embolism) and safety (major bleeding and nonmajor clinically relevant bleeding

68 rrhosis patients with regard to new onset of major bleeding and outcome.

69 Safety outcome was major bleeding and procedure-related complications.

70 Rates of major bleeding and recurrent venous thromboembolism were

71 No difference was shown for major bleeding and there was a trend toward a reduction

72 8 years after CD diagnosis, the incidence of major bleeding and thrombotic events was 2.5 and 18.7 pe

73 f diagnosis, 10.9% and 13.9% had experienced major bleeding and thrombotic events, respectively.

74 ary endpoint was the cumulative incidence of major bleeding and vascular access site complications at

75 f tracheal stenosis and an increased risk of major bleeding and wound infection for surgical tracheos

76 oral access site-related life-threatening or major bleedings and vascular complications were absent i

77 (1.8%; 95% confidence interval, 0.7-3.0) had major bleeding, and 28 patients (5.2%; 95% confidence in

78 =0.021) but a similar risk of death, stroke, major bleeding, and all-cause hospitalization.

79 Rates of stroke or systemic embolism, major bleeding, and all-cause mortality increased as ren

80 lated the hazard ratios for ischemic stroke, major bleeding, and fatal bleeding stratified by these q

81 the association of WCM with ischemic stroke, major bleeding, and fatal bleeding, using a subset of pa

82 ncluded transfusion of other blood products, major bleeding, and major complications.

83 e of recurrent venous thromboembolism (VTE), major bleeding, and mortality in patients with symptomat

84 The risks of stroke or systemic embolism, major bleeding, and mortality were higher in patients wi

85 tional Society on Thrombosis and Haemostasis major bleeding, and the net clinical outcome of S/SE/maj

86 Rates of recurrent venous thromboembolism, major bleeding, and unrelated death did not differ betwe

87 ic embolism; HR, 1.56; 95% CI, 1.27-1.93 for major bleeding; and HR, 2.31; 95% CI, 1.98-2.68 for mort

88 ti-factor Xa activity in patients with acute major bleeding associated with factor Xa inhibitors, wit

89 target vessel revascularization, stroke, and major bleeding at 12 months post-stenting.

90 osite of recurrent venous thromboembolism or major bleeding at 18 months after randomization.

91 reduced composite end point of death and/or major bleeding at 30 days in the bivalirudin arm of the

92 or noncoronary artery bypass graft protocol major bleeding at 30 days) were lower with radial access

93 d not result in significantly lower rates of major bleeding at 48 h (6.9% vs. 9.0%; relative risk: 0.

94 therapy, bivalirudin did not reduce rates of major bleeding at 48 h or net adverse cardiovascular eve

95 Thrombolysis In Myocardial Infarction (TIMI) major bleeding at 9 months.

96 and death unrelated to pulmonary embolism or major bleeding, at 18 and 42 months.

97 et vessel revascularization) and in-hospital major bleeding based on access site adopted (radial vers

98 ce in the prevalence of tracheal stenosis or major bleeding between percutaneous and surgical tracheo

99 Safety outcomes included major bleeding, blood transfusion, and hospitalization f

100 th, major adverse cardiovascular events, and major bleeding but did not affect the relative efficacy

101 gher risk of stroke or systemic embolism and major bleeding but show consistent benefits with the 5 m

102 APT was also associated with a lower risk of major bleeding, but a higher risk of myocardial infarcti

103 ated with reductions in overall mortality or major bleeding, but was associated with a lower rate of

104 evented myocardial infarctions and increased major bleedings, but the strength of evidence for these

105 o fibrinolytic therapy increased the risk of major bleeding by 1.27-8.82-times compared with accelera

106 ial infarction, stroke or systemic embolism, major bleeding, cause-specific hospitalization, and deat

107 Safety outcomes included major bleeding, clinically relevant nonmajor bleeding, a

108 proved 30-day clinical outcomes with reduced major bleeding compared with heparins plus optional glyc

109 e outcome of recurrent venous thrombosis and major bleeding compared with placebo.

110 for recurrent VTE and an increased risk for major bleeding compared with short-term treatment in pat

111 varoxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77

112 The prognostic impact of site-specific major bleeding complications after percutaneous coronary

113 Clinicians should minimize the risk of major bleeding complications during PCI through judiciou

114 as associated with a significant decrease in major bleeding complications requiring reoperation (RR,

115 n scintigraphy or in the safety endpoints of major bleeding, contrast-induced nephropathy, or stroke

116 6 months, symptomatic deep vein thrombosis, major bleeding, death at 3 and 6 months, and filter comp

117 Major bleeding, defined as hospitalization or emergency

118 th from any cause, myocardial infarction, or major bleeding during 180 days of follow-up.

119 osite of recurrent venous thromboembolism or major bleeding during the 12 months after randomization,

120 None of the patients had spontaneous major bleeding during the course of OAC after device imp

121 New onset of major bleeding during the stay at the intensive care uni

122 Among patients with severe trauma and major bleeding, early administration of plasma, platelet

123 No major bleeding episodes occurred; 2 patients in each tre

124 umber needed to treat with ACDs to prevent 1 major bleeding event is high.

125 ar complications (6.3% vs. 3.4%; p < 0.001), major bleeding events (10.5% vs. 8.5%; p = 0.003), and s

126 score was significantly better in predicting major bleeding events (Delong test, all P < 0.05, apart

127 ex concentrates (PCCs) for the management of major bleeding events (MBEs) on rivaroxaban or apixaban.

128 ted with the absence of investigator-defined major bleeding events (OR: 1.46;95% CI: 1.00-2.15).

129 the HAS-BLED score were 0.72 (0.65-0.79) for major bleeding events and 0.83 (0.75-0.91) for ICH (all

130 mprovement (NRI) of 17.1-65.5% in predicting major bleeding events and 29.5-67.3% in predicting ICH (

131 was associated with lower odds than LMWH of major bleeding events and death both in-hospital and up

132 and the remaining eight (14%) events (three major bleeding events and five clinically relevant non-m

133 Fondaparinux was associated with reduced major bleeding events and improved survival compared wit

134 The differences in major bleeding events and mortality between the 2 treatm

135 = .001) in the LMWH arm and no difference in major bleeding events but evidence of an increase in the

136 y is to provide an overview of site-specific major bleeding events in contemporary PCI and study thei

137 conclusion, HAS-BLED categorised adjudicated major bleeding events in low-risk and high-risk patients

138 tation in patients with previous spontaneous major bleeding events is associated with low risk of rec

139 atients; and apixaban, 12886 patients), 4770 major bleeding events occurred during 447037 person-quar

140 No major bleeding events occurred.

141 er 1000 treated patients per year but 6 more major bleeding events than shorter-duration DAPT.

142 Estimated excess major bleeding events were 1.39 (CI, 0.70 to 2.28) for G

143 The numbers of major bleeding events were as follows: five of 152 patie

144 Major bleeding events were centrally adjudicated.

145 Previous major bleeding events were major gastrointestinal bleedi

146 Major bleeding events were recorded after a median of 6.

147 Pharmacomechanical thrombolysis led to more major bleeding events within 10 days (1.7% vs. 0.3% of p

148 ding events and five clinically relevant non-major bleeding events) required elective surgical or int

149 f these heavy menstrual bleeding events (two major bleeding events, 17 clinically relevant non-major

150 Of the 127 adjudicated major bleeding events, 21.3% of events occurred in 'low-

151 bleeding events, 17 clinically relevant non-major bleeding events, 32 minor bleeding events) were tr

152 placebo group, which required PCI, and five major bleeding events, including two in the PCI group an

153 , conferred significant risk for adjudicated major bleeding events.

154 y of this strategy in patients with previous major bleeding events.

155 ll-cause mortality, stroke, reoperation, and major bleeding events.

156 h and 30- and 180-day death, MI, stroke, and major bleeding events.

157 omes included the primary safety endpoint of major bleeding, fatal bleeding, intracranial haemorrhage

158 ell transfusions, platelet transfusions, and major bleeding following cardiac surgery.

159 e of tracheal stenosis, wound infection, and major bleeding for surgical tracheostomies.

160 es ranged from 0.3% to 1.1% among groups for major bleeding, from 0.2% to 0.9% for pulmonary embolism

161 , which was associated with a higher risk of major bleeding (hazard ratio: 2.19; 95% confidence inter

162 o: 0.84; 95% CI: 0.74 to 0.95) but increased major bleeding (hazard ratio: 2.32; 95% CI: 1.68 to 3.21

163 tion=0.99) and provided even greater safety (major bleeding: higher dose pinteraction 0.02, lower dos

164 ial infarction, stroke or systemic embolism, major bleeding, hospitalization, or death within 30 days

165 on parameters for prediction of new onset of major bleeding; however, further studies are required to

166 76-0.93) and as safe as VKAs with respect to major bleeding (HR, 0.83; 95% CI, 0.69-1.01).

167 c embolism (HR, 1.47; 95% CI, 1.20-1.81) and major bleeding (HR, 1.89; 95% CI, 1.62-2.20) compared wi

168 : 1.29; 95% CI: 1.16 to 1.43; p <0.001), and major bleeding (HR: 1.21; 95% CI: 1.03 to 1.42; p = 0.02

169 icted ischemic stroke (HR=1.45, P<0.001) and major bleeding (HR=1.57, P<0.001) independently, regardl

170 D; p interaction [pint] = 0.26; and for less major bleeding, HR: 0.74; 95% CI: 0.53 to 1.02 in patien

171 nce interval [CI]: 1.49 to 2.38; p < 0.001), major bleeding (HRadj: 1.30; 95% CI: 1.04 to 1.64; p = 0

172 tio, 1.03; 95% CI, 0.79 to 1.33; P=0.85) and major bleeding in 1.6% (hazard ratio, 1.10; 95% CI, 0.84

173 lidated a new biomarker-based risk score for major bleeding in 14,537 patients with atrial fibrillati

174 ratio, 0.84; 95% CI, 0.60 to 1.19; P=0.33), major bleeding in 8.6% and 8.6%, respectively (hazard ra

175 t no statistically significant difference in major bleeding in apixaban-treated patients.

176 onal HAS-BLED and the newer ORBIT scores for major bleeding in both the derivation cohort (0.68 [95%

177 The HR for major bleeding in group A1 versus group A2 was 3.78 (95%

178 gest independent predictors for new onset of major bleeding in multivariate regression analysis.

179 Major bleeding in patients on higher-dose NOACs versus w

180 (ischemic stroke and systemic embolism) and major bleeding in patients treated in routine clinical p

181 y dose of apixaban compared with warfarin on major bleeding in patients with 1 dose-reduction criteri

182 ty, major adverse cardiovascular events, and major bleeding in patients with ACS undergoing invasive

183 risk score to improve the prognostication of major bleeding in patients with atrial fibrillation.

184 s without diabetes, there was increased TIMI major bleeding in patients with diabetes (HR: 2.56; 95%

185 d without concurrent medications and risk of major bleeding in patients with nonvalvular atrial fibri

186 two cardiac perforations and three cases of major bleeding in the ablation group and two deaths from

187 The potent P2Y12 inhibitors increased major bleeding in women (HR: 1.28; 95% CI: 0.87 to 1.88)

188 Analysis of major bleeding included events during study drug treatme

189 heir relatives carry not only a high risk of major bleeding, including postpartum hemorrhage, but als

190 non-major bleeding was unrelated to age, but major bleeding increased steeply with age (>/=75 years h

191 The primary end point was the composite of major bleeding, INR of 4 or greater, venous thromboembol

192 guided dosing, reduced the combined risk of major bleeding, INR of 4 or greater, venous thromboembol

193 or systemic embolism, myocardial infarction, major bleeding (International Society of Thrombosis and

194 ) for stroke/systemic embolic events (SSEE), major bleeding, intracranial hemorrhage (ICH), and all-c

195 thout routine PPI use, the long-term risk of major bleeding is higher and more sustained in older pat

196 However, major bleeding is increasingly recognized as the Achille

197 rmal renal and liver function, stroke, prior major bleeding, labile international normalized ratios,

198 RR2HAGES improved their predictive value for major bleeding leading to improved clinical usefulness c

199 a for the assessment of the effectiveness of major bleeding management.

200 (CTEs) at the expense of increasing risk for major bleeding (MB).

201 Major bleeding occurred at similar rates among the patie

202 ult in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group

203 Major bleeding occurred in 1 patient (0.1%) in the treat

204 Major bleeding occurred in 13 (9%) patients (11 [8%] gra

205 Major bleeding occurred in 17 of 571 patients in the Fii

206 Major bleeding occurred in 1773 (24.1%) patients, and ma

207 Major bleeding occurred in 36 patients (6.9%) in the edo

208 placebo group (HR, 0.15; 95% CI, 0.05-0.43); major bleeding occurred in 4 patients in the warfarin gr

209 Similarly, major bleeding occurred in 79 (3%) of 2474 patients with

210 Major bleeding occurred in 8.9% of DCS and 9.2% of BMS p

211 Major bleeding occurred in 9 patients (all in the GP gro

212 Major bleeding occurred in ten (3%) of 378 patients with

213 Overall bivalirudin caused less major bleeding (odds ratio [OR], 0.64; 95% confidence in

214 as the only independent predictor of reduced major bleeding (odds ratio, 0.45; 95% CI, 0.27-0.74; P=0

215 %/year (HR: 0.74, 95% CI: 0.55 to 0.98), and major bleeding of 1.86%/year versus 3.06%/year (HR: 0.61

216 concomitant aspirin had annual rates of any major bleeding of 3.07% (2.70-3.44) and thromboembolism

217 net adverse clinical events (a composite of major bleeding or a major adverse cardiovascular event).

218 In patients with major bleeding or at risk for hemorrhagic complications,

219 eeding, and the net clinical outcome of S/SE/major bleeding or death were evaluated by intention-to-t

220 Among patients not sustaining major bleeding or ischemic events 1 year after PCI, a pr

221 1 year of dual antiplatelet therapy without major bleeding or ischemic events to an additional 18 mo

222 cohort, the association between spontaneous major bleeding or MI after PCI and long-term mortality.

223 nically significant bleeding (a composite of major bleeding or minor bleeding according to Thrombolys

224 The safety endpoint was major bleeding or other clinically relevant bleeding, as

225 The first 3 months after a major bleeding or surgical procedure were excluded from

226 (OR, 0.85; 95% CI: 0.12, 5.84; P = .87), and major bleeding (OR, 0.56; 95% CI: 0.21, 1.51; P = .25).

227 (OR, 0.25; 95% CI: 0.12, 0.50; P < .01), and major bleeding (OR, 0.61; 95% CI: 0.49, 0.77; P < .01).

228 .15; P=0.41), but lower rates of in-hospital major bleeding (OR, 0.62; 95% CI, 0.40-0.98; P=0.04) and

229 (OR, 0.21; 95% CI: 0.10, 0.45; P < .01), and major bleeding (OR, 0.64; 95% CI: 0.51, 0.80; P < .01).

230 I, 0.98-1.72; P=0.06), with no difference in major bleeding (OR, 1.47; 95% CI, 0.39-5.63; P=0.57) wit

231 0.65-1.26; P=0.56), and an increased risk of major bleeding (OR, 1.49; 95% CI, 1.06-2.11; P=0.02).

232 39-1.05) and weak evidence of an increase in major bleeding (OR, 1.66; 95% credible intervals, 0.89-3

233 lism, vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome

234 th (p < 0.0001), and from 0.591 to 0.629 for major bleeding (p < 0.0001).

235 between cirrhosis patients with and without major bleeding (P < 0.01 for all).

236 e to warfarin, with additional reductions in major bleeding, particularly hemorrhagic stroke, and mor

237 Patients were followed up for 30 days for major bleeding (primary outcome), minor bleeding, arteri

238 al, 0.76-1.19; interaction P=0.313), as were major bleeding rates (>/=75 years: 4.86% rivaroxaban ver

239 rrhage, and mortality, with lower to similar major bleeding rates compared with warfarin.

240 Annualized major bleeding rates were similar across AF patterns (2.

241 imary effectiveness and safety outcomes were major bleeding, recurrent venous thromboembolism, and al

242 P<0.001; number needed to treat, 16.7), and major bleeding (relative risk, 0.83; 95% confidence inte

243 A significantly lower major bleeding risk in comparison with VKA was observed

244 t share metabolic pathways that may increase major bleeding risk.

245 the clinically guided group were 2 vs 8 for major bleeding (RR, 0.24; 95% CI, 0.05-1.15), 56 vs 77 f

246 RR, 0.86 [CI, 0.75 to 0.98]; P = 0.025), and major bleeding (RR, 0.57 [CI, 0.37 to 0.88]; P = 0.011).

247 Aspirin increased the risk for major bleeding (RR, 1.54; 95% CI, 1.30-1.82), and statin

248 evidence showed that DAPT increased risk for major bleeding (RR, 1.63 [CI, 1.34 to 1.99]).

249 roke or systemic embolism (primary outcome), major bleeding (safety outcome), and mortality were exam

250 emia-driven target vessel revascularization, major bleeding, sepsis, pneumonia, peritonitis, severe a

251 rrence but causes more major adverse events, major bleeding, sinus node dysfunction, and pacemaker im

252 In case of major bleeding, surgical or interventional treatment was

253 on, and stent thrombosis, but lower rates of major bleeding than did patients treated with 1-year DAP

254 ted incidence rates per 1000 person-years of major bleeding than NOACs alone: 38.09 for NOAC use alon

255 rapeutic window for edoxaban is narrower for major bleeding than thromboembolism.

256 oxaban is effective and associated with less major bleeding than warfarin.

257 A nonsignificantly higher risk of major bleeding than with VKA was observed with dabigatra

258 For major bleeding, the addition of vWF to HAS-BLED improved

259 cal outcomes, with significant reductions in major bleeding, thrombocytopenia, and transfusions compa

260 TRA with in-hospital clinical end points of major bleeding, transfusion, and death.

261 Bleeding Academic Research Consortium (BARC) major bleeding unrelated to coronary artery bypass graft

262 The difference was driven by BARC major bleeding unrelated to coronary artery bypass graft

263 The absolute excess of TIMI major bleeding was 0.12% (number needed to harm: 834).

264 , 95% CI 0.77-1.22); cumulative incidence of major bleeding was 0.3% (95% CI 0.2-0.5; 11 of 3633 pati

265 score-adjusted population, the frequency of major bleeding was 0.8% (19/2505) in the rivaroxaban gro

266 The incidence of major bleeding was 1.3% in the no-bridging group and 3.2

267 %/year (HR: 0.93, 95% CI: 0.83 to 1.05), and major bleeding was 2.18%/year versus 3.03%/year (HR: 0.7

268 The rate of major bleeding was 2.4 per 100 person-years at 6 months

269 ality in cirrhosis patients with and without major bleeding was 89% and 68%, respectively (P < 0.05 b

270 Major bleeding was also similar across the 3 treatment a

271 On Cox regression analysis, adjudicated major bleeding was associated only with HAS-BLED (HR: 1.

272 The most common site of major bleeding was gastrointestinal, occurring in 130 [2

273 us thromboembolism was lower but the rate of major bleeding was higher with edoxaban than with daltep

274 TIMI major bleeding was increased with ticagrelor 60 mg at ea

275 Although major bleeding was increased, fatal or critical organ bl

276 th from any cause, myocardial infarction, or major bleeding was not lower among those who received bi

277 No major bleeding was recorded, and no patient died during

278 C use alone, the adjusted incidence rate for major bleeding was significantly lower for concurrent us

279 Major bleeding was similar between treatment groups (sev

280 Long-term freedom from stroke or major bleeding was superior after the Ross procedure (Ro

281 Risk of non-major bleeding was unrelated to age, but major bleeding

282 Rates of major bleeding were 0.5% in the group receiving 20 mg of

283 At 2 years, multivariate correlates of major bleeding were age >75 years, anemia, raised plasma

284 r (CV) death, MI, and stroke as well as TIMI major bleeding were analyzed at yearly landmarks (years

285 npatient admissions for ischemic strokes and major bleeding were compared across the 3 drugs (rivarox

286 on rates of stroke or systemic embolism and major bleeding were consistent in patients with normal o

287 No thrombosis or major bleeding were seen.

288 The most important predictors for major bleeding were the concentrations of the biomarkers

289 use significantly increased the risk for any major bleeding when compared with warfarin (hazard ratio

290 nd was associated with a similar risk of any major bleeding when compared with warfarin and dabigatra

291 ecutive patients with history of spontaneous major bleeding while on OAC who had subsequently undergo

292 The primary outcome was spontaneous major bleeding while receiving short-term postprocedural

293 tive risks for thrombosis, any bleeding, and major bleeding with antiplatelet therapy compared with n

294 Increased major bleeding with heparin administration cannot be exc

295 d with 0 to 4 medications had lower rates of major bleeding with rivaroxaban (adjusted hazard ratio,

296 tudy, we evaluated 67 patients who had acute major bleeding within 18 hours after the administration

297 es of symptomatic venous thromboembolism and major bleeding within 3 months after the procedure.

298 The 2 primary endpoints were major bleeding within 48 h or before hospital discharge

299 iple therapy versus DAPT had higher rates of major bleeding without a measurable difference in compos

300 dence rates of thrombosis, any bleeding, and major bleeding without antiplatelet therapy ranged from